MA37569B1 - Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc - Google Patents
Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gccInfo
- Publication number
- MA37569B1 MA37569B1 MA37569A MA37569A MA37569B1 MA 37569 B1 MA37569 B1 MA 37569B1 MA 37569 A MA37569 A MA 37569A MA 37569 A MA37569 A MA 37569A MA 37569 B1 MA37569 B1 MA 37569B1
- Authority
- MA
- Morocco
- Prior art keywords
- gcc
- antibody molecules
- relates
- methods
- immunoconjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37569B1 true MA37569B1 (fr) | 2020-08-31 |
Family
ID=49477498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37569A MA37569B1 (fr) | 2012-04-27 | 2013-04-27 | Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366890B (es) | 2009-10-23 | 2019-07-30 | Millennium Pharm Inc | Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados. |
| WO2015058301A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| ES2754282T3 (es) | 2014-02-14 | 2020-04-16 | Bioventures Llc | Aductos acetaminofén proteína y procedimientos de uso de los mismos |
| AU2015358373B2 (en) | 2014-12-03 | 2021-05-27 | Arkansas Children's Research Institute | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| US11090383B2 (en) | 2015-10-01 | 2021-08-17 | Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| US11473081B2 (en) * | 2016-12-12 | 2022-10-18 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| CN117038018A (zh) * | 2017-12-06 | 2023-11-10 | 文塔纳医疗系统公司 | 存储和检索数字病理学分析结果的方法 |
| US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| JPWO2021246413A1 (enExample) * | 2020-06-02 | 2021-12-09 | ||
| CA3205007A1 (en) * | 2020-12-17 | 2022-06-23 | Parasol Biotech Ltd. | Gucy2c binding molecules and uses thereof |
| MX2023011862A (es) * | 2021-04-07 | 2024-01-08 | Lg Chemical Ltd | Polipeptido de union a gucy2c y usos del mismo. |
| US20260091061A1 (en) * | 2022-09-28 | 2026-04-02 | Legend Biotech Ireland Limited | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
| US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| CN121866270A (zh) * | 2023-09-21 | 2026-04-14 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| CN120965861B (zh) * | 2025-10-22 | 2026-02-13 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| ES2216004T3 (es) | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| EP0951475B1 (en) | 1996-05-03 | 2003-07-16 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US20010039016A1 (en) | 2000-03-27 | 2001-11-08 | Waldman Scott A. | Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CN1489474A (zh) | 2001-01-26 | 2004-04-14 | Ӣϣ��̩��˹��˾ | 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法 |
| JP4206272B2 (ja) | 2001-03-29 | 2009-01-07 | サイナージィ ファーマスーティカルズ、インコーポレイテッド | 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| WO2003057838A2 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1599165A4 (en) | 2003-02-10 | 2010-09-08 | Univ Jefferson | THE USE OF GCC LIGANDS |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| US8563682B2 (en) | 2004-06-25 | 2013-10-22 | Thomas Jefferson University | Guanylylcyclase C ligands |
| ES2371083T3 (es) | 2004-12-21 | 2011-12-27 | Medimmune Limited | Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos. |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| CA2696011A1 (en) * | 2007-08-10 | 2009-02-19 | Centocor Ortho Biotech Inc. | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| MY161564A (en) | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| KR101651796B1 (ko) * | 2007-11-30 | 2016-08-26 | 제넨테크, 인크. | Ｖｅｇｆ 다형성 및 항―혈관신생 요법 |
| US20110195415A1 (en) | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| EP2296685B1 (en) | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010065293A1 (en) * | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| JP5979877B2 (ja) * | 2009-02-12 | 2016-08-31 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト癌における変異ｒｏｓ発現 |
| WO2010096929A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
| WO2010104035A1 (ja) * | 2009-03-12 | 2010-09-16 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
| WO2010147684A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| WO2011066048A1 (en) | 2009-10-22 | 2011-06-03 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
| MX366890B (es) * | 2009-10-23 | 2019-07-30 | Millennium Pharm Inc | Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados. |
| AU2011261161A1 (en) * | 2010-06-01 | 2013-01-10 | Ludwig Institute For Cancer Research Limited | Antibodies directed to the unprocessed receptor tyrosine kinase c-Met |
| SG187109A1 (en) * | 2010-08-13 | 2013-03-28 | Hoffmann La Roche | Neuropilin as a biomarker for bevacizumab combination therapies |
| US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| EP2961424A4 (en) * | 2013-02-28 | 2016-10-19 | Millennium Pharm Inc | ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER |
-
2013
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja not_active Expired - Fee Related
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491977A1 (ru) | Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии | |
| Pisa et al. | Parkinson's disease: a comprehensive analysis of fungi and bacteria in brain tissue | |
| WO2009085216A3 (en) | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease | |
| MA46648B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
| EP2117604A4 (en) | METHOD AND COMPOSITION FOR IMPROVED F-18 MARKING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | |
| MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
| WO2008103645A3 (en) | Prostate cancer and melanoma antigens | |
| Moore et al. | A Photoacoustic‐Fluorescent Imaging Probe for Proteolytic Gingipains Expressed by Porphyromonas gingivalis | |
| MA49158B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
| EP2987807A3 (en) | Antibodies recognising phospho-tau | |
| JP2018532777A5 (enExample) | ||
| MA29615B1 (fr) | Preparations et methodes pour le diagnostic et le traitement d'une tumeur | |
| BR112013033258A2 (pt) | moléculas de ligação de anti-alfa sinucleína | |
| BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
| TR201800669T4 (tr) | Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇ | |
| MX2015008448A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos. | |
| Libner et al. | Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis | |
| Olatunji et al. | Prostate-specific membrane antigen-targeted turn-on probe for imaging cargo release in prostate cancer cells | |
| Dahis et al. | Monitoring melanoma responses to sting agonism and focused ultrasound thermal ablation using microneedles and ultrasensitive single molecule arrays | |
| Turtzo et al. | Failure of intravenous or intracardiac delivery of mesenchymal stromal cells to improve outcomes after focal traumatic brain injury in the female rat | |
| Ferguson et al. | Using magnetic resonance imaging to evaluate dendritic cell-based vaccination | |
| Kim et al. | In Situ Detection of HY-Specific T Cells in Acute Graft-versus-Host Disease–Affected Male Skin after Sex-Mismatched Stem Cell Transplantation | |
| WO2018039810A1 (en) | Provision of a therapeutically active cell product | |
| Larenkov et al. | Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development | |
| Peng et al. | Bioorthogonal optimized virus immuno-nanomedicine (BOVIN) |